1507 results about "Complementarity determining region" patented technology

The invention relates to a nano antibody targeting cadherin 17 and application thereof, and relates to the technical field of immunology and molecular biology, the amino acid sequence of a complementary determining region of the nano antibody targeting cadherin 17 comprises CDR1 shown as any one of SEQ ID NO: 21-32, CDR2 shown as any one of SEQ ID NO: 34-45, and CDR3 shown as any one of SEQ ID NO: 47-58. According to the invention, an alpaca immune phage display library is constructed, a series of nano antibody molecules targeting cadherin 17 (CDH17) are screened from the alpaca immune phage display library, and functions and applications of the nano antibody are verified at various levels of CDH17 antigen protein, CDH17 target cells, CDH17 CAR-T cells and the like.

The invention discloses an antibody for resisting HPV16 type E6 protein and E7 protein, a detection product and application of the antibody and the detection product, and relates to the technical field of monoclonal antibodies. The antibody comprises a heavy chain complementarity determining region in a heavy chain variable region as shown in SEQ ID NO: 1 and a light chain complementarity determining region in a light chain variable region as shown in SEQ ID NO: 2. The antibody can be specifically combined with HPV16 E6 protein and E7 protein, and a detection product for detecting the HPV16 E6 / E7 antigen can be developed based on the antibody provided by the invention. Tests show that a kit developed based on the monoclonal antibody has the advantages of high detection sensitivity, rapidness and strong tolerance on the HPV16 E6 / E7 antigen, can be used for quality control in the production process of the recombinant human HPV16 E6 / E7 antigen, and can efficiently and accurately quantify the antigen content in a vaccine and monitor the quality of the vaccine.

Provided herein are antibodies that specifically bind to MICA / B having a heavy chain, a light chain, a variable heavy chain domain (VH), a variable light chain domain (VL), and a complementarity determining region (CDR) disclosed herein, as well as methods and uses thereof.

The present invention belongs to the field of biological detection technology, specifically relating to a monoclonal antibody combination for detecting HPV18 E7 protein and its application. This combination consists of monoclonal antibodies 5F8 and 6G6, wherein the heavy and light chain variable regions of 5F8 and 6G6, respectively, contain specific complementarity-determining region sequences (as shown in SEQ ID NOs. 1 to 12), conferring high specificity for HPV18 E7 protein. Verification using a double-antibody sandwich ELISA and a biotin-avidin amplification system demonstrated that this antibody combination specifically recognizes HPV18 E7 protein, exhibits no cross-reactivity with other high-risk HPV oncoproteins, and exhibits a detection sensitivity of 1 ng / mL. This combination can be used to construct detection systems such as ELISA kits and immunochromatographic test strips, suitable for rapid screening of HPV18 E7 protein in cervical exfoliated cell samples.

The invention discloses an anti-interleukin-6 antibody or a reagent and a kit for detecting interleukin-6, and relates to the field of antibodies. The anti-interleukin-6 antibody disclosed by the invention comprises a heavy chain complementarity determining region and a light chain complementarity determining region, provides an important raw material source for detection of interleukin-6, and has good affinity or activity.

The invention discloses an anti-cortisol antibody or a cortisol detection reagent and kit, and relates to the field of antibodies. The anti-cortisol antibody disclosed by the invention comprises a heavy chain complementarity determining region and a light chain complementarity determining region, provides an important raw material source for detection of cortisol, and has good affinity or activity.

The invention provides an anti-human CD117 monoclonal antibody and an application thereof. The anti-human CD117 monoclonal antibody comprises three heavy chain complementary determining regions CDR-H1, CDR-H2 and CDR-H3 and three light chain complementary determining regions CDR-L1, CDR-L2 and CDR-L3, the amino acid sequence of the CDR-H1 is as shown in SEQ ID NO: 1, the amino acid sequence of the CDR-H2 is as shown in SEQ ID NO: 2, the amino acid sequence of the CDR-H3 is as shown in SEQ ID NO: 3, the amino acid sequence of the CDR-L1 is as shown in SEQ ID NO: 4, the amino acid sequence of the CDR-L2 is as shown in SEQ ID NO: 5, and the amino acid sequence of the light chain complementary determining regions is as shown in SEQ ID NO: 6. The amino acid sequence of the CDR-L3 is as shown in SEQ ID NO: 6. Compared with the existing known anti-human CD117 monoclonal antibody, the antibody disclosed by the invention shows better cellular level biology, and is expected to show a good clinical effect in the aspect of preventing and treating related diseases.

The invention belongs to the field of antibody preparation and protein detection, and particularly relates to a monoclonal antibody pair for detecting IGFBP2 protein or IGFBP2 polypeptide and application of the monoclonal antibody pair. The monoclonal antibody pair provided by the invention comprises a first antibody and a second antibody, the first antibody comprises a 14F8 antibody or a 8F1 antibody; the second antibody comprises a 6F2 antibody or a 9G1 antibody. According to the present invention, the amino acid sequences of the complementary determining regions CDR1, CDR2 and CDR3 of the light chain and heavy chain variable regions of the monoclonal antibody are determined, the IGFBP2 protein or IGFBP2 polypeptide can be specifically detected, the specificity is strong, the sensitivity is high, the IGFBP2 protein in human serum can be detected, and the basis is provided for the diagnosis and treatment of clinical tumor patients.

The invention discloses an anti-human hepatitis B e antigen monoclonal antibody and application thereof, and relates to the technical field of hepatitis B detection. In a heavy chain variable region of the monoclonal antibody, an amino acid sequence of a complementarity determining region CDR1-3 is as shown in SEQ ID NO.1-3 or has at least 95% of homology with the sequence as shown in SEQ ID NO.1-3; in the light chain variable region, amino acid sequences of complementary determining regions CDR1 and CDR3 are shown as SEQ ID NO.4 and SEQ ID NO.5 or have at least 95% of homology with the sequences shown as SEQ ID NO.4 and SEQ ID NO.5, and an amino acid sequence of a complementary determining region CDR2 is FAS. The monoclonal antibody provided by the invention can well recognize a natural hepatitis B e antigen, and the titer of a supernatant cultured by a B cell can reach 1: 10000, so that the monoclonal antibody can be completely applied to detection research of the human hepatitis B e antigen. The chemiluminescence reagent prepared by using the monoclonal antibody has the advantages of high specificity, strong anti-interference capability, high detection sensitivity, good stability and the like, almost has no leak detection, and can replace an imported reagent.

The present invention relates to the field of biomedicine, and specifically provides an antibody binding to IL-11 or antigen-binding fragment thereof, comprising three heavy-chain complementarity-determining regions respectively represented by HCDR1, HCDR2, and HCDR3, and three light-chain complementarity-determining regions respectively represented by LCDR1, LCDR2, and LCDR3, the antibody or antigen-binding fragment thereof being selected from A-I, A-II, A-III, or A-IV. The provided antibody or antigen-binding fragment thereof has high binding capacity to the IL-11 antigen and can block the IL-11 antigen from binding to receptors thereof, thus effectively inhibiting the pro-fibrotic effect of IL-11 and inhibiting or preventing the generation or proliferation of fibroblasts, and can be effectively used for treating or preventing human fibrotic diseases, inflammation, cancers, or autoimmune diseases.

The present invention belongs to the field of biological detection technology, and specifically relates to an anti-monkey C-reactive protein monoclonal antibody, an enzyme-linked immunosorbent assay kit and its application. Named CRP-13, CRP-13 includes a heavy chain variable region and a light chain variable region; the heavy chain variable region has three complementary determining regions CDR-H1 to CDR-H3, and the amino acid sequences are shown in SEQ ID NO.6-SEQ ID NO.8; the light chain variable region has three complementary determining regions CDR-L1 to CDR-L3, and the amino acid sequences are shown in SEQ ID NO.9-SEQ ID NO.11. The monoclonal antibody of the present invention can specifically bind to monkey C-reactive protein with high specificity. The above monoclonal antibody can be used to screen a paired monoclonal antibody, and a monkey C-reactive protein enzyme-linked immunosorbent assay kit is obtained based on the combination of the monoclonal antibodies, which can detect the content of monkey C-reactive protein in monkey serum, plasma or tissue fluid.

The invention relates to a humanized nano antibody targeting cadherin 17 and application of the humanized nano antibody, and relates to the technical field of immunology and molecular biology. The complementarity determining region of the humanized nano antibody comprises a CDR1 of which the amino acid sequence is shown as SEQ ID NO: 2, a CDR2 of which the amino acid sequence is shown as SEQ ID NO: 4 and a CDR3 of which the amino acid sequence is shown as SEQ ID NO: 6; a framework region of the humanized nano antibody comprises an FR1 of which the amino acid sequence is shown as any one of SEQ ID NO: 1 and SEQ ID NO: 8, an FR2 of which the amino acid sequence is shown as any one of SEQ ID NO: 3, SEQ ID NO: 9 and SEQ ID NO: 11, an FR3 of which the amino acid sequence is shown as any one of SEQ ID NO: 5 and SEQ ID NO: 10, and an FR4 of which the amino acid sequence is shown as SEQ ID NO: 7. According to the humanized nano-antibody, the immunogenicity of the nano-antibody is reduced, the targeted binding activity and killing activity are improved, and the humanized nano-antibody can be used for developing immunodetection reagents, CAR-T / NK cell drugs and antibody drugs.

The invention belongs to the technical field of biological detection, and particularly relates to a monoclonal antibody combination for detecting cat FGF23 protein and application. The invention provides a monoclonal antibody combination with high specificity and strong sensitivity aiming at cat FGF23 protein. The antibody combination comprises monoclonal antibodies 5A2 and 3A1. By designing and optimizing complementary determining region (CDR) sequences of heavy chain and light chain variable regions, CDR amino acid sequences are respectively shown as SEQ ID NO.1 to SEQ ID NO.12, and the antibody combination has excellent binding activity and detection specificity. A double-antibody sandwich ELISA detection method constructed on the basis of the antibody combination has relatively high sensitivity, and the accuracy of a detection result is remarkably improved.

The invention relates to the field of in-vitro immunodiagnosis detection, in particular to an IgG antibody, an IgM antibody and a method. The invention provides an IgG (immunoglobulin G) antibody specifically bound with coxsackie virus, which is characterized in that amino acid sequences of complementary determining regions CDRH1-CDRH3 of a heavy chain variable region of the IgG antibody are respectively shown as SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3; the amino acid sequences of the complementary determining regions CDRL1-CDRL3 of the light chain variable region are respectively as shown in SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6. The IgG antibody provided by the invention not only has good specificity and can specifically recognize the coxsackie virus, but also has high sensitivity and stability.

The invention belongs to the technical field of immunology, and particularly relates to an anti-IL-6 humanized nano antibody, a recombinant humanized nano antibody and application. The inventor-derived nano antibody 2H3 comprises complementary determining regions CDR1-CDR3, the amino acid sequence of the CDR1 is as shown in SEQ ID NO.13, the amino acid sequence of the CDR2 is as shown in SEQ ID NO.14, and the amino acid sequence of the CDR3 is as shown in SEQ ID NO.15. The inventor-derived nano antibody 2H3 has the advantages that the complementary determining regions CDR1-CDR3 can be used for preparing the antibody; the humanized nano antibody can block the combination of IL-6 and a receptor thereof while keeping the affinity with IL-6, and has a wide application prospect in the preparation of medicines for preventing and / or treating tumors. The humanized nano antibody is low in molecular weight, reduces the immune risk caused by heterology, is more beneficial to penetrating a blood brain barrier, and is easier to reach the interior of a tumor to play a therapeutic effect.

The invention discloses an anti-norovirus monoclonal antibody and application thereof, and discloses an anti-VP1 protein monoclonal antibody, complementarity determining regions HCDR1, HCDR2 and HCDR3 of a heavy chain variable region of the monoclonal antibody are as shown in SEQ ID NO: 1-3, complementarity determining regions LCDR1 and LCDR3 of a light chain variable region of the monoclonal antibody are as shown in SEQ ID NO: 4-5, and the amino acid sequence of the complementarity determining region LCDR2 of the light chain variable region is NAK. The anti-norovirus monoclonal antibody disclosed by the invention has strong affinity and high binding activity with norovirus type 1 VP1 protein, and is an excellent monoclonal antibody for detecting and treating norovirus.

The invention discloses an antibody for resisting HPV16 and / or HPV18 type E2 protein and application of the antibody, and relates to the technical field of biological medicine. The antibody comprises a heavy chain complementarity determining region in a heavy chain variable region as shown in SEQ ID NO: 1 and a light chain complementarity determining region in a light chain variable region as shown in SEQ ID NO: 2. The antibody can be specifically combined with HPV16 and / or HPV18 type E2 protein. Based on the antibody provided by the invention, a reagent, a kit, a test strip, an antibody chip, an antibody probe or a detector for detecting the HPV16 and / or HPV18 type E2 antigen can be developed. Tests show that a kit developed based on the monoclonal antibody has the advantages of high detection sensitivity, good specificity / specificity, high precision, high accuracy, fast detection and strong tolerance, and can be used for quality control in the production process of recombinant human HPV16 and / or HPV18 type E2 antigens.

The invention relates to the technical field of biological detection, in particular to a monoclonal antibody combination for HPV18 type E6 protein detection and application. The provided combination is composed of 5G3 and 2C7, and the amino acid sequences of complementary determining regions of variable regions of a heavy chain and a light chain of the combination are clear and are respectively shown as SEQ ID NO.1-12. The antibody combination has high specificity and sensitivity, the lowest detection limit can reach 100 pg / ml, and cross reaction with other HPV subtypes is avoided. According to a double-antibody sandwich ELISA and biotin-avidin amplification detection system constructed based on the combination, the signal intensity and the detection accuracy are remarkably improved, and the combination is suitable for rapid detection of the HPV18 type E6 protein in a cervical exfoliated cell sample and has application value in early diagnosis of cervical cancer, risk stratification, vaccine research and development and curative effect evaluation.

The invention provides a nano antibody and application thereof, a variable region in an amino acid sequence of the nano antibody comprises a complementarity determining region CDR and a framework region FR, the complementarity determining region CDR comprises a complementarity determining region CDR1, a complementarity determining region CDR2 and a complementarity determining region CDR3, the CDR3 is RWPDXY family, and binding sites of the CDR3 and AAV capsid are W99, D101 and Y103. The nano antibody provided by the invention has very high affinity and activity, and can specifically recognize and combine various serotypes of AAV, and an adsorbent prepared from the nano antibody has very strong adsorption capacity on AAV, can be applied to AAV affinity chromatography, and is beneficial to industrial application of an AAV affinity chromatography column. In addition, the method can also be applied to the field of AAV detection, and can detect empty capsid and virions together.

This invention belongs to the field of biological detection technology, specifically relating to a monoclonal antibody combination for detecting feline NT-proBNP protein and its applications. The monoclonal antibody combination of the present invention comprises monoclonal antibodies 3A6 and 5H5. These two antibodies possess unique heavy and light chain variable region complementarity-determining regions, respectively, and their amino acid sequences have been fully defined (SEQ ID NOs. 1-12). This antibody combination can specifically recognize and efficiently bind to feline NT-proBNP protein, making it suitable for the development of a highly sensitive and specific diagnostic tool for feline cardiomyopathy. By constructing a double-antibody sandwich ELISA assay system, the minimum detection limit can reach 100 pg / mL, and it exhibits excellent specificity and stability.

The invention belongs to the technical field of biological detection, and particularly relates to a monoclonal antibody combination for detecting measles virus nucleoprotein and application of the monoclonal antibody combination. The combination is composed of monoclonal antibodies 5E2 and 5G9 and can efficiently and specifically recognize measles virus nucleoprotein, amino acid sequences of complementary determining regions (CDR) of heavy chain and light chain variable regions of the combination are clear and are shown as SEQ ID NO.1-12 respectively, high specificity and high affinity of the antibodies are guaranteed, the antibody combination can effectively capture and detect target antigens, and the antibody combination can be used for detecting measles virus nucleoprotein. The risk of non-specific binding and cross reaction is obviously reduced. The combination shows excellent sensitivity and specificity in detection platforms such as colloidal gold immunochromatography, and provides a stable and reliable biological recognition tool for rapid and accurate detection of measles viruses.

The present invention relates to the field of biological medicine, and particularly provides an IL-11 binding antibody or an antigen binding fragment thereof, the antibody comprises three heavy chain complementarity determining regions represented by HCDR1, HCDR2 and HCDR3 respectively and three light chain complementarity determining regions represented by LCDR1, LCDR2 and LCDR3 respectively, and the antibody or the antigen binding fragment thereof is selected from A-I, A-II, A-III or A-IV. The antibody or the antigen binding fragment thereof provided by the invention has relatively high binding capacity with the IL-11 antigen, and can block the binding of the IL-11 antigen and a receptor thereof, so that the fibrosis promoting effect of the IL-11 is effectively inhibited, the generation or proliferation of fibrocytes is inhibited or prevented, and the anti-fibrosis effect of the IL-11 is improved. The compound can be effectively used for treating or preventing human fibrosis diseases, inflammations, cancers or autoimmune diseases.

The invention belongs to the field of biological medicine, and relates to an anti-SEZ6 nano antibody or antigen binding fragment and application. The anti-SEZ6 nano antibody or the antigen binding fragment comprises three complementary determining regions, namely, CDR1, CDR2 and CDR3; the sequences of all the regions are respectively shown as SEQ ID NO: 1 to SEQ ID NO: 18. Compared with a conventional antibody, the anti-SEZ6 nano antibody is efficient in expression, simple in purification, small in molecular weight, high in affinity, relatively good in specificity, high in solubility and strong in tolerance, and can be widely applied to the fields of scientific research, diagnosis and treatment.

The invention discloses an anti-interleukin 6 antibody or a reagent and a kit for detecting interleukin 6, and relates to the field of antibodies. The anti-interleukin 6 antibody disclosed by the invention comprises a heavy chain complementarity determining region and a light chain complementarity determining region, provides an important raw material source for detection of interleukin 6, and has good affinity and activity.

The invention relates to an anti-VIM nano antibody and application thereof, belongs to the technical field of biology, and aims to solve the problem of Vimentin VIM detection, and has the key points that a complementary determining region CDR of the nano antibody comprises CDR1, CDR2 and CDR3 sequences: (I): (1) the amino acid sequence of the CDR1 is shown as SEQ ID NO.27, and (2) the amino acid sequence of the CDR2 is shown as SEQ ID NO.33; and (3) the amino acid sequence of the CDR3 is shown as SEQ ID NO.39. The nano antibody and the polypeptide thereof have the effects that the nano antibody and the polypeptide thereof have very high affinity and activity, can specifically recognize and combine with VIM, can be used for capturing and detecting VIM positive cells, and can be applied to immunofluorescence analysis or immunohistochemical analysis and the like through a proper antibody labeling technology.

The invention discloses an antibody for resisting HPV16 and / or HPV18 type E2 protein, an antibody conjugate and application of the antibody conjugate, and relates to the technical field of medical biology. The antibody comprises a heavy chain complementarity determining region in a heavy chain variable region as shown in SEQ ID NO: 1, and a light chain complementarity determining region in a light chain variable region as shown in SEQ ID NO: 2. Tests show that a kit developed based on the monoclonal antibody has the advantages of high detection sensitivity, good specificity, high intermediate precision, high accuracy, consistent linear range of standard curves, fast detection and strong tolerance for the HPV16 and / or HPV18 type E2 antigen, can be used for quality control in the production process of the recombinant human HPV16 and / or HPV18 type E2 antigen, and has wide application prospects. The antigen content in the vaccine can be efficiently and accurately quantified, and the quality of the vaccine can be monitored.

The invention discloses a PD-1 (programmed death-1) monoclonal antibody and application thereof, the invention provides the monoclonal antibody, an antibody heavy chain complementarity determining region comprises CDR-H1, CDR-H2 and CDR-H3 which are respectively shown as SEQ ID NO.1-3, and an antibody light chain complementarity determining region comprises CDR-L1, CDR-L2 and CDR-L3 which are respectively shown as SEQ ID NO.4, LAS (LAS) and SEQ ID NO.5.

The invention discloses an anti-cortisol antibody or a cortisol detection reagent and kit, and relates to the field of antibodies. The anti-cortisol antibody disclosed by the invention comprises a heavy chain complementarity determining region and a light chain complementarity determining region, provides an important raw material source for detection of cortisol, and has good affinity or activity.

The invention discloses an anti-TP53 mutation T cell receptor and application thereof, the T cell receptor comprises specific alpha chain and beta chain variable domains, and the complementary determining region (CDR) sequence is shown as SEQ ID NO: 9-14. The TCR has the core advantage that the TCR has excellent broad-spectrum recognition capability, can target six different amino acid substitutions (A, G, I, N, S and T) at the R249 site, and effectively deals with tumor heterogeneity and mutation difference between patients. Aiming at high-frequency HLA-B * 07: 02 alleles in people, the TCR lays a foundation for developing TCR-T cell therapy covering a wide range of people, and has great clinical application value and market potential in treatment of various solid tumors carrying TP53 R249 hotspot mutation, such as liver cancer.

The invention discloses a shark source nano antibody targeting an FPV-VP2 protein and an application of the shark source nano antibody. The amino acid sequence of the complementarity determining region 3 of the shark source nano antibody is selected from any one of the sequences shown in SEQ ID NO.16 to SEQ ID NO.30, or a sequence having homology with the sequence shown in any one of the sequences shown in SEQ ID NO.16 to SEQ ID NO.30; the amino acid sequence of the shark source nano antibody is selected from any one of the sequences shown in SEQ ID NO.1-SEQ ID NO.15, or the amino acid sequence of the shark source nano antibody is selected from any one of the sequences shown in SEQ ID NO.1-SEQ ID NO.15, or a sequence having homology with the sequence shown in any one of the sequences shown in SEQ ID NO.1-SEQ ID NO.15. The shark source VNAR nano antibody has the advantages of small molecular weight, high affinity, high stability, easiness in genetic engineering modification, low production cost and the like.